Isolation and Analysis of Tumor-Derived Exosomes.
TEX
exosome isolation
exosomes
size exclusion chromatography
Journal
Current protocols in immunology
ISSN: 1934-368X
Titre abrégé: Curr Protoc Immunol
Pays: United States
ID NLM: 9101651
Informations de publication
Date de publication:
12 2019
12 2019
Historique:
entrez:
26
11
2019
pubmed:
26
11
2019
medline:
8
7
2020
Statut:
ppublish
Résumé
A method for isolation of exosomes from tumor cell supernatants or cancer patients' plasma is presented. Tumor-derived exosomes (TEX) are defined as a subset of extracellular vesicles (EVs) sized at 30 to 150 nm and originating from multivesicular bodies (MVBs). The method utilizes size exclusion chromatography (SEC) for recovery of exosomes from cell-line supernatants or cancer patients' plasma. The recovered exosomes are morphologically intact, aggregate-free, and functionally competent. Their molecular content parallels that of the parent tumor cells and they carry various immunoregulatory ligands known to modulate functions of immune cells. All exosomes isolated from tumor cell lines are TEX, while those isolated from plasma of cancer patients have to be fractionated into TEX and non-TEX. Mini-SEC allows for exosome isolation and recovery in quantities sufficient for molecular profiling, functional studies, and, in the case of plasma, further fractionation into TEX and non-TEX. The mini-SEC method can also be used for comparative studies of the exosome content in serial specimens of cancer patients' body fluids. © 2019 by John Wiley & Sons, Inc.
Identifiants
pubmed: 31763776
doi: 10.1002/cpim.91
pmc: PMC6880756
mid: NIHMS1046334
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e91Subventions
Organisme : NCI NIH HHS
ID : R01 CA168628
Pays : United States
Organisme : NCI NIH HHS
ID : R21 CA205644
Pays : United States
Informations de copyright
© 2019 John Wiley & Sons, Inc.
Références
PLoS One. 2010 Jul 22;5(7):e11469
pubmed: 20661468
J Extracell Vesicles. 2015 Jul 06;4:27378
pubmed: 26154623
J Extracell Vesicles. 2015 Mar 26;4:27269
pubmed: 25819214
J Control Release. 2015 Dec 10;219:278-294
pubmed: 26143224
Methods. 2012 Feb;56(2):293-304
pubmed: 22285593
Front Biosci (Landmark Ed). 2011 Jan 01;16:411-21
pubmed: 21196178
Front Oncol. 2013 May 17;3:107
pubmed: 23730621
Eur J Immunol. 2012 Jul;42(7):1778-84
pubmed: 22585706
Proc Natl Acad Sci U S A. 2013 Apr 30;110(18):7312-7
pubmed: 23589885
Cancer Res. 2010 Dec 1;70(23):9621-30
pubmed: 21098712
Front Immunol. 2014 Apr 10;5:160
pubmed: 24782865
Small. 2018 Feb;14(6):
pubmed: 29282861
Mol Cancer Res. 2018 Nov;16(11):1798-1808
pubmed: 30042174
Curr Protoc Cell Biol. 2006 Apr;Chapter 3:Unit 3.22
pubmed: 18228490
J Extracell Vesicles. 2016 Mar 24;5:29289
pubmed: 27018366
Sci Rep. 2017 Oct 31;7(1):14684
pubmed: 29089618
J Extracell Vesicles. 2018 Feb 15;7(1):1435138
pubmed: 29511460
J Immunol. 2011 Feb 15;186(4):2219-28
pubmed: 21242526
Cell Mol Life Sci. 2018 Jan;75(2):193-208
pubmed: 28733901
Clin Exp Immunol. 2018 Jun;192(3):271-283
pubmed: 29431869
J Immunol. 2009 Sep 15;183(6):3720-30
pubmed: 19692638
J Immunol Methods. 2014 Sep;411:55-65
pubmed: 24952243
J Extracell Vesicles. 2018 Nov 23;7(1):1535750
pubmed: 30637094
Lab Chip. 2010 Feb 21;10(4):505-11
pubmed: 20126692
Clin Cancer Res. 2017 Aug 15;23(16):4843-4854
pubmed: 28400428
J Natl Cancer Inst. 2014 Dec 12;107(1):363
pubmed: 25505237
Methods Mol Biol. 2011;728:235-46
pubmed: 21468952
J Extracell Vesicles. 2016 Oct 31;5:32945
pubmed: 27802845
J Extracell Vesicles. 2014 Sep 08;3:null
pubmed: 25279113
Exp Cell Res. 2019 May 15;378(2):149-157
pubmed: 30857972